AR and neoplasm: In this context, abiraterone, a selective and irreversible CYP17A1 inhibitor that suppresses androgen biosynthesis in the testes, adrenal glands, and tumor microenvironment, is recognized for its ability to reduce circulating testosterone and dihydrotestosterone levels, thereby limiting ligand availability to the androgen receptor (AR) [28].